Segment
Drug modalities: the six kinds of thing a medicine can be
A medicine is a molecule, a protein, a set of instructions, or a living cell. Which one it is decides how it is discovered, how it is made, what a dose costs, how it reaches a patient and how long the exclusivity lasts — so modality is the most useful first division in the industry.
In one sentence
A drug modality is the class of molecule or biological entity a therapy is built from — small molecule, monoclonal antibody, nucleic acid, engineered cell, or synthetic peptide — each with its own discovery, manufacturing and delivery characteristics.
For most of pharmaceutical history a drug was a small organic molecule, made by chemical synthesis, taken as a tablet. That modality is still the largest by prescription volume, and it remains the only one that is reliably cheap, orally available and stable at room temperature — three properties the newer classes have mostly not matched.
The biologics that followed are proteins, made by living cells rather than synthesised. They can hit targets small molecules cannot, they must be injected because the digestive system would destroy them, and they cost far more to manufacture. Everything about the industry's economics over the past two decades follows from that trade.
The newest classes go further: instructions the body translates into a protein, a short synthetic strand that silences one the body is already making, or a patient's own cells engineered and returned. They open genuinely new treatment categories and they bring manufacturing and logistics problems the previous modalities did not have — which is why several of them are limited by production capacity rather than by demand.
How this breaks down
Split by what the therapeutic entity actually is, because everything downstream follows from it.
- Small moleculesChemical synthesis, oral availability, and the patent cliff that defines the business model.Definition pageChokepoint
- Monoclonal antibodiesHow an antibody drug is made, why titre matters, and why biosimilars are not generics.Definition pageChokepoint
- mRNA and lipid nanoparticlesMaking the body produce the protein, and the delivery particle that made it possible.Breaks down into: mRNA synthesis · Lipid nanoparticles2 pages belowChokepoint
- Cell and gene therapyEngineered cells and viral vectors, one-time dosing, and manufacturing that runs one patient at a time.Breaks down into: Engineered cell therapy · In vivo gene therapy2 pages belowChokepoint
- Peptides and GLP-1Solid-phase synthesis, long-acting design, and why the constraint was filling devices rather than making drug.Definition pageChokepoint
- Oligonucleotide therapeuticsChemically synthesised nucleic acid drugs, sugar-conjugated liver targeting, and dosing measured in months.Definition pageChokepoint
What this depends on
2 of these are marked as a chokepoint: a handful of qualified suppliers, a multi-year lead time, or a single geography.
- Supply chainChokepoint
Biomanufacturing capacity
Every biological modality needs cell culture, purification and sterile filling capacity that takes years to build.
Biomanufacturing - StandardChokepoint
Regulatory approval
No modality reaches a patient without it, and the evidence standard differs by class.
Regulatory approval - Technology
Analytical characterisation
Identity, purity and potency are established by measurement, and no batch of any modality is released without it.
Analytical instruments - Supply chain
Downstream purification
Every biological modality has to be separated from the cells, vectors and reagents that made it, and that train is where most of the yield goes.
Purification
Companies across Drug modalities
Every company named on a step below this page, ordered by how many of those steps it appears at. Compiled from the pages themselves rather than written separately, so the two cannot disagree. Not a ranking and not a recommendation.
- Lonza GroupSwitzerland7 steps
Small molecules · Monoclonal antibodies · mRNA synthesis · Lipid nanoparticles · Cell and gene therapy · Engineered cell therapy · In vivo gene therapy
- Roche HoldingSwitzerland3 steps
Monoclonal antibodies · In vivo gene therapy · Oligonucleotide therapeutics
- Miltenyi BiotecPrivate2 steps
33 more companies appear at a single step each; they are named on the pages for those steps.
How these pages are written
Each page explains one technology in plain language, states what it depends on, and names companies by what they supply at that step. Company roles are described qualitatively and deliberately carry no market shares, revenue figures or rankings — those change faster than an explainer can, and a stale number is worse than none. Ticker links point at company pages on this site and are provided for reference only.
Nothing here is investment advice, a recommendation, or a forecast. A company named on a page about a technology is not thereby a good investment, and the chokepoints described are structural facts about supply chains rather than predictions about prices. Technology moves; where a page describes something as unresolved or in development, that was true when it was written.